Tokai Pharma (TKAI) Posts Q1 Loss of 59c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Reddit to join S&P 500 index on Aug. 18, shares leap
- Should you chase this mini rally in gold? Citi weighs in
Oppenheimer Starts Tokai Pharmaceuticals (TKAI) at Outperform
May 12, 2015 6:06 AM EDTOppenheimer initiates coverage on Tokai Pharmaceuticals (NASDAQ: TKAI) with a Outperform rating and a price target of $38.00, citing the company's novel agent for treating prostate cancer where others fail.
Analyst Ling Wang commented, "We are initiating coverage of Tokai Pharmaceuticals, Inc.... More
